Viral Vitalism

Source Library

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

Exenatide AUD RCT with neuroimaging subgroup; primary drinking endpoint mixed overall.

StudyGovernment health research
Source type
Study
Access type
Abstract/index
Publisher
PubMed
Indexed by
PubMed
Date
2022
Added
2026-06-19

Trust profile

91

Government health research

Publisher type
Government research
Bias profile
Low

Best used for

  • Research synthesis
  • Public-health context
  • Safety resources

Weak for

  • Primary endpoint extraction when a study is available

Used in Viral Vitalism

Claims supported

  • Early randomized human studies suggest GLP-1 receptor agonists may reduce some alcohol craving or drinking outcomes, but the evidence is not yet sufficient for routine addiction treatment.

Related studies

Related sources

Topic tags

glp-1exenatidealcohol-use-disorderreward-circuitry

Vital Signals

Get the weekly health signal without the wellness fog.

A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.

No spam. No miracle claims. Just better health signal.

By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.